A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy
A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy
批准号:
9883646
负责人:
Yi Tan
金额:
$38.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-01 至 2022-02-28
关键词:
5&apos-AMP-activated protein kinaseAdhesionsApoptosisBone MarrowCXCR4 ReceptorsCXCR4 geneCardiacCardiac MyocytesCardiovascular DiseasesCardiovascular systemCatalytic DomainCell DeathCell physiologyCellsCessation of lifeChemotaxisChronicCytoskeletal ModelingDataDevelopmentDiabetes MellitusDiabetic AngiopathiesDiabetic mouseDysplasiaExposure toFamilyFutureGTP-Binding ProteinsGenesGrowth FactorHeartHigh Fat DietIn VitroInfarctionInjectionsInjuryInsulin-Dependent Diabetes MellitusInterleukin-6IschemiaKnock-outKnockout MiceLife StyleLipidsMAP Kinase GeneMediatingModelingMusMyocardialMyocardial InfarctionMyocardial IschemiaNon-Insulin-Dependent Diabetes MellitusOxidative StressPalmitatesPaperPathogenesisPathogenicityPathologicPathologyPhosphorylationPhosphotransferasesPreventionProcessProductionProtein KinaseReperfusion InjuryRoleSignal PathwaySignal TransductionSiteStreptozocinStromal Cell-Derived Factor 1SystemTestingTherapeuticTissuesTransgenesTransgenic OrganismsTransplantationVentricular septumantioxidant therapybasebeta-arrestincardiac angiogenesiscardiac regenerationchemokineclinical investigationclinical practiceconditional knockoutconventional therapydiabeticdiabetic cardiomyopathydiabetic patientglycemic controlheart damagehypertension controlimprovedin vivoinsightnew therapeutic targetnovelp38 Mitogen Activated Protein Kinasepreventreceptorreceptor expressionstem cellstreatment strategy
中文摘要
糖尿病心肌病(DCM)是糖尿病患者的主要慢性并发症之一。传统型
治疗扩张型心肌病的治疗方法包括控制血糖、控制高血压、降脂和
生活方式的管理。然而,目前还没有专门针对
扩张型心肌病的发病机制。需要对扩张型心肌病的致病机制有更深入的了解
改进治疗策略。
基质细胞衍生因子-1(SDF-1)属于C-X-C基序趋化因子家族。它控制着不同的细胞
通过与其受体CXCR4和CXCR7相互作用而发挥作用。心肌SDF-1一过性上调
在缺血期间或脑梗塞后,可将干细胞吸引到损伤部位,从而促进心脏
再生和血管生成。外源性SDF-1有助于预防心肌梗死和
通过干细胞依赖和非依赖机制造成的缺血/再灌注损伤。然而,这个角色
SDF-1-CXCR4/CXCR7系统在DCM中的作用机制尚未建立。
越来越多的证据表明,糖尿病导致的SDF-1等生长因子缺乏是
与糖尿病心血管并发症有关。在一项初步研究中,PI显示
SDF-1在1型和2型糖尿病小鼠心脏组织中的表达显著下调,
而受体的表达水平不受影响。PI认为心脏SDF-1的缺乏可能
有助于DCM,补充SDF-1可能提供直接的心肌保护作用。作为初步测试
培养的心肌细胞暴露于SDF-1预处理的类似棕榈酸酯的糖尿病脂肪毒性。
这些研究表明,SDF-1通过CXCR7-保护棕榈酸酯诱导的细胞死亡,但不能
CXCR4-,介导AMP激活的蛋白激酶(AMPK)激活。研究结果具有重要意义。
因为他们证明SDF-1可以提供独立于糖尿病心脏细胞死亡的直接保护
干细胞。因此,确定体内保护是否涉及相同的直接作用至关重要。
在分离的心肌细胞上鉴定出SDF-1。基于CXCR4和CXCR7在
心血管疾病,假设SDF-1治疗糖尿病小鼠直接预防
CXCR7介导的AMPK激活介导的糖尿病心肌细胞死亡和心脏重构
而SDF-1治疗最终可以预防DCM。
这一假设将通过三个具体的目标来检验:(1)确定心肌细胞的直接影响
研究SDF-1对DCM的保护作用;(2)确定SDF-1信号是否通过CXCR7介导
对DCM的保护,独立于CXCR4;(3)确定AMPK是否介导SDF-1/CXCR7
针对DCM的保护。
该项目将为SDF-1-CXCR4和/或-CXCR7在
心肌细胞作为未来临床研究中预防DCM的新治疗靶点。
英文摘要
Diabetic cardiomyopathy (DCM) is one of the major chronic complications in diabetic patients. Conventional
therapies for treatment of DCM include glycemic control, management of hypertension, lowering lipid and
life-style management. However, there are no treatment strategies available that specifically target the
pathogenesis of DCM. Greater understanding of the pathogenic mechanism of DCM is needed to develop
improved therapeutic strategies.
Stromal cell-derived factor-1 (SDF-1) belongs to C-X-C motif chemokine family. It controls diverse cell
functions by interacting with its receptors, CXCR4 and CXCR7. Myocardial SDF-1 is transiently up-regulated
during ischemia or after infarction and can attract stem cells to the injury site contributing to cardiac
regeneration and angiogenesis. Exogenous SDF-1 can help prevent myocardial infarction and
ischemia/reperfusion injury through stem cell-dependent and -independent mechanisms. However, the role
and mechanism of the SDF-1-CXCR4/CXCR7 system in DCM has not been established.
Accumulating evidence indicates that diabetes-induced deficiency of growth factors such as SDF-1 is
associated with diabetic cardiovascular complications. In a preliminary study, the PI showed that the
expression of SDF-1 is notably down-regulated in the cardiac tissue of mice with type 1 and type 2 diabetes,
while the receptor expression levels are unaffected. The PI considered that lack of cardiac SDF-1 may
contribute to DCM and supplementary SDF-1 may provide direct cardiomyocyte protection. As an initial test
cultured cardiac cells were exposed to palmitate-mimicked diabetic lipotoxicity with SDF-1 pretreatment.
These studies showed that SDF-1 protected against palmitate-induced cell death via CXCR7-, but not
CXCR4-, mediated AMP-activated protein kinase (AMPK) activation. The results are of great significance
since they demonstrate SDF-1 can provide direct protection against diabetic cardiac cell death independent
of stem cells. Therefore, it is critical to determine if in vivo protection involves the same direct actions by
SDF-1 identified on isolated cardiomyocytes. Based on the critical role of CXCR4 and CXCR7 in
cardiovascular diseases, it is hypothesized that SDF-1 treatment of diabetic mice directly protects against
diabetes-induced cardiomyocyte death and cardiac remodeling via CXCR7-mediated activation of AMPK
and that SDF-1 treatment can ultimately prevent DCM.
This hypothesis will be tested through three specific aims: (1) to determine the direct cardiomyocyte effects
of SDF-1 in protection against DCM; (2) to determine whether SDF-1 signaling through CXCR7 mediates
protection against DCM, independently of CXCR4; (3) to determine whether AMPK mediates SDF-1/CXCR7
protection against DCM.
This project will provide fundamental evidence for the interaction of SDF-1-CXCR4 and/or -CXCR7 at the
cardiomyocyte as a new therapeutic target for the prevention of DCM in future clinical investigations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
-
批准号:10345440
-
项目类别:
-
资助金额:$55.36万
-
财政年份:2021
-
负责人:Yi Tan
-
依托单位:
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
-
批准号:10531887
-
项目类别:
-
资助金额:$54.56万
-
财政年份:2021
-
负责人:Yi Tan
-
依托单位:
海外基金